IBO — Universal Ibogaine Income Statement
0.000.00%
Last trade - 00:00- CA$7.72m
- CA$10.04m
- CA$2.33m
Annual income statement for Universal Ibogaine, fiscal year end - July 31st, CAD millions except per share, conversion factor applied.
2022 July 31st | 2023 July 31st | 2024 July 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 1.07 | 1.03 | 2.33 |
| Cost of Revenue | |||
| Gross Profit | 0.497 | -0.028 | 0.552 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Depreciation and Amortization | |||
| Unusual Expense / Income | |||
| Total Operating Expenses | 9.23 | 2.97 | 4.24 |
| Operating Profit | -8.15 | -1.94 | -1.9 |
| Total Net Non Operating Interest Income / Expense | |||
| Gain / Loss on Sale of Assets | |||
| Total Net Non Operating Interest Income / Expense | |||
| Other Net Non Operating Costs | |||
| Net Income Before Taxes | -10.5 | -2.39 | -2.05 |
| Net Income After Taxes | -10.5 | -2.39 | -2.05 |
| Net Income Before Extraordinary Items | |||
| Net Income | -10.5 | -2.39 | -2.05 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -10.5 | -2.39 | -2.05 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -0.027 | -0.011 | -0.005 |